Literature DB >> 17485388

Protein isoprenylation in biology and disease: general overview and perspectives from studies with genetically engineered animals.

Dolores Perez-Sala1.   

Abstract

The posttranslational modification of proteins by lipids is a key mechanism in the regulation of protein localization and function. Isoprenylation is a process critical for the membrane association of a plethora of signalling proteins with fundamental roles in cell biology, including G proteins and nuclear lamins. Isoprenylation is irreversible but is frequently associated to reversible posttranslational modifications, such as palmitoylation or phosphorylation, that act like switches that modulate the dynamics of protein-membrane or protein-protein interactions and target the modified proteins to specific membrane compartments. The severe phenotype of animals deficient in the enzymes involved in isoprenylation and postprenylation processing highlights the significance of these processes. Moreover, alterations in the genes involved in the maturation of isoprenylated proteins have been found at the basis of some severe human diseases, like choroideremia or the premature ageing progeria syndromes. Given their critical role in the transformation potential of the Ras oncogenes, isoprenylation and postprenylation processing are targets for the development of inhibitors with antitumoral activity. The recent generation of animal models genetically engineered to target the enzymes involved in isoprenylation and associated modifications has unveiled unpredicted aspects of these modifications. Moreover, these models are proving of crucial importance for the elucidation of the mechanisms of disease, and the identification and validation of therapeutic targets. This review attempts to summarize general aspects of the posttranslational modification of proteins by isoprenylation, paying special attention to the evidences obtained from the use of genetically engineered animals and the avenues that these models open.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17485388     DOI: 10.2741/2401

Source DB:  PubMed          Journal:  Front Biosci        ISSN: 1093-4715


  19 in total

1.  Evidence for prenylation-dependent targeting of a Ykt6 SNARE in Plasmodium falciparum.

Authors:  Lawrence Ayong; Thiago DaSilva; Jennifer Mauser; Charles M Allen; Debopam Chakrabarti
Journal:  Mol Biochem Parasitol       Date:  2010-11-12       Impact factor: 1.759

Review 2.  The balance of protein farnesylation and geranylgeranylation during the progression of nonalcoholic fatty liver disease.

Authors:  Yue Zhao; Tian-Yu Wu; Meng-Fei Zhao; Chao-Jun Li
Journal:  J Biol Chem       Date:  2020-03-05       Impact factor: 5.157

3.  Measurement of protein farnesylation and geranylgeranylation in vitro, in cultured cells and in biopsies, and the effects of prenyl transferase inhibitors.

Authors:  Norbert Berndt; Saïd M Sebti
Journal:  Nat Protoc       Date:  2011-10-27       Impact factor: 13.491

4.  Effect of cholesterol reduction on receptor signaling in neurons.

Authors:  Kenji Fukui; Heather A Ferris; C Ronald Kahn
Journal:  J Biol Chem       Date:  2015-09-14       Impact factor: 5.157

5.  Regulation of polyisoprenylated methylated protein methyl esterase by polyunsaturated fatty acids and prostaglandins.

Authors:  Felix Amissah; Shalina Taylor; Randolph Duverna; Lambert T Ayuk-Takem; Nazarius S Lamango
Journal:  Eur J Lipid Sci Technol       Date:  2011-11       Impact factor: 2.679

Review 6.  Isoprenoids and related pharmacological interventions: potential application in Alzheimer's disease.

Authors:  Ling Li; Wei Zhang; Shaowu Cheng; Dongfeng Cao; Marc Parent
Journal:  Mol Neurobiol       Date:  2012-03-15       Impact factor: 5.590

7.  Inhibition of polyisoprenylated methylated protein methyl esterase by synthetic musks induces cell degeneration.

Authors:  Lambert Ayuk-Takem; Felix Amissah; Byron J Aguilar; Nazarius S Lamango
Journal:  Environ Toxicol       Date:  2012-04-04       Impact factor: 4.119

8.  Targeting protein prenylation for cancer therapy.

Authors:  Norbert Berndt; Andrew D Hamilton; Saïd M Sebti
Journal:  Nat Rev Cancer       Date:  2011-10-24       Impact factor: 60.716

Review 9.  Targeting the mevalonate cascade as a new therapeutic approach in heart disease, cancer and pulmonary disease.

Authors:  Behzad Yeganeh; Emilia Wiechec; Sudharsana R Ande; Pawan Sharma; Adel Rezaei Moghadam; Martin Post; Darren H Freed; Mohammad Hashemi; Shahla Shojaei; Amir A Zeki; Saeid Ghavami
Journal:  Pharmacol Ther       Date:  2014-02-26       Impact factor: 12.310

10.  A novel statin-mediated "prenylation block-and-release" assay provides insight into the membrane targeting mechanisms of small GTPases.

Authors:  Bassam R Ali; Ian Nouvel; Ka Fai Leung; Alistair N Hume; Miguel C Seabra
Journal:  Biochem Biophys Res Commun       Date:  2010-05-13       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.